冠状动脉旁路移植术后1年维持单药治疗中氯吡格雷与阿司匹林的效果比较
本研究纳入671例冠状动脉旁路移植术后维持1年双联抗血小板治疗且移植物均通畅的患者,按倾向评分匹配227对,比较氯吡格雷(272例)与阿司匹林(399例)单药维持治疗的4年结局。两组全因死亡、主要不良事件及术后5年移植物新发闭塞率均无显著差异,但阿司匹林组更多患者需更换抗血小板方案(22.8% vs 2.2%,P<0.001)。
要点
- CABG术后1年DAPT稳定患者中,氯吡格雷与阿司匹林单药维持的4年生存和主要不良事件无显著差异。
- 术后5年移植物造影新发闭塞率两组无统计学差异(患者水平P=0.39,远端吻合口水平P=0.63)。
- 阿司匹林组需更换抗血小板方案的比例显著高于氯吡格雷组(22.8% vs 2.2%,P<0.001)。
核心结论
- 在CABG术后接受DAPT并稳定1年的患者中,氯吡格雷或阿司匹林单药维持治疗在4年全因死亡、主要不良事件及新发移植物闭塞方面均无显著差异。
- 但服用阿司匹林的患者更多需要将抗血小板方案更换为其他抗血小板或抗凝治疗。
研究设计与样本
- 研究纳入2009年1月至2015年12月间CABG术后维持1年DAPT且1年随访造影显示所有移植物通畅、随后转换为单药抗血小板治疗的患者671例,其中氯吡格雷组272例、阿司匹林组399例。
- 采用倾向评分匹配分析,按1:1比例匹配227对。
- 比较4年随访期间的总死亡率、心性死亡及主要不良事件(包括全因死亡、急性心肌梗死、冠状动脉再干预或再手术、缺血性卒中及大出血)。
- 术后5年通过移植物造影评估移植物通畅性。
主要发现
- 未匹配队列4年随访总生存率组间无显著差异(HR 1.24,95%CI 0.71-2.15,P=0.46),主要不良事件发生率亦无显著差异(HR 1.22,95%CI 0.77-1.92,P=0.41)。
- 倾向评分匹配后总生存率组间仍无显著差异(HR 1.05,95%CI 0.55-2.01,P=0.89),主要不良事件发生率亦无显著差异(HR 1.01,95%CI 0.60-1.73,P=0.96)。
- 术后5年移植物造影显示,氯吡格雷组与阿司匹林组患者水平新发移植物闭塞率分别为3.2%和4.7%(P=0.39),远端吻合口水平新发闭塞率分别为1.2%和1.6%(P=0.63),均无统计学差异。
- 自单药抗血小板治疗开始,阿司匹林组22.8%(91/399)需更换抗血小板方案,氯吡格雷组2.2%(6/272)需更换(P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Data on the safety and efficacy of clopidogrel (CPD) monotherapy after coronary artery bypass grafting (CABG) are limited. We compared the clinical outcomes and graft patency rates during 4 years in CABG patients who maintained CPD or aspirin after 1 year of dual antiplatelet therapy (DAPT) use. METHODS: A total of 671 patients who maintained 1-year DAPT after CABG with all grafts patent on one-year follow-up angiography and switched to single antiplatelet therapy (SAPT) using CPD (n = 272) or aspirin (n = 399) between January 2009 and December 2015 were enrolled. Propensity score matching analysis was used, and 227 pairs were matched in a 1:1 ratio. Overall mortality, cardiac mortality, and major adverse events, including all-cause mortality, acute myocardial infarction, coronary reintervention or reoperation, ischaemic stroke, and major bleeding, were compared. Graft patency was evaluated using graft angiography 5 years post-surgery. RESULTS: Overall survival and the incidence of major adverse events during the 4-year follow-up did not differ significantly between the groups when un-matched (hazard ratio [HR], 95% confidence interval [CI]=1.24, 0.71 to 2.15, P = 0.46 and HR, 95% CI = 1.22, 0.77 to 1.92, P = 0.41, respectively) or matched (HR, 95% CI = 1.05, 0.55 to 2.01, P = 0.89 and HR, 95% CI = 1.01, 0.60 to 1.73, P = 0.96, respectively). In the postoperative 5-year graft angiography, new graft occlusion was found in 3.2% and 4.7% of patients and newly occurred graft occlusion rates of distal anastomoses were 1.2% and 1.6% in the CPD and aspirin groups, respectively, and were not statistically different between the 2 groups (P = 0.39 and 0.63, respectively). Changes of antiplatelet regimen were needed in 22.8% (91 of 399) of aspirin group and in 2.2% (6 of 272) of CPD group from the initiation of SAPT (P < 0.001). CONCLUSIONS: In this series of patients undergoing CABG who received DAPT and remained stable for 1 year, SAPT maintenance with CPD or aspirin did not show any significant differences in 4-year outcomes such as all-cause mortality, major adverse events, and newly occurring graft occlusion. However, more patients taking aspirin required changes in antiplatelet regimens to other antiplatelet or anticoagulation therapies.
引用
- Kim JS, Kang Y, Sohn SH, et al. Comparative effectiveness of clopidogrel versus aspirin as a maintenance monotherapy 1 year after coronary artery bypass grafting. Eur J Cardiothorac Surg. 2023. PMID: 37039835. doi:10.1093/ejcts/ezad128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。